Phospholamban R14del disease: The past, the present and the future
Publication date
2023
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Arrhythmogenic cardiomyopathy affects significant number of patients worldwide and is characterized by life-threatening ventricular arrhythmias and sudden cardiac death. Mutations in multiple genes with diverse functions have been reported to date including phospholamban (PLN), a key regulator of sarcoplasmic reticulum (SR) Ca2+ homeostasis and cardiac contractility. The PLN-R14del variant in specific is recognized as the cause in an increasing number of patients worldwide, and extensive investigations have enabled rapid advances towards the delineation of PLN-R14del disease pathogenesis and discovery of an effective treatment. We provide a critical overview of current knowledge on PLN-R14del disease pathophysiology, including clinical, animal model, cellular and biochemical studies, as well as diverse therapeutic approaches that are being pursued. The milestones achieved in <20 years, since the discovery of the PLN R14del mutation (2006), serve as a paradigm of international scientific collaboration and patient involvement towards finding a cure.
Keywords
arrhythmias, cardiomyopathy, phospholamban, precision medicine, R14del mutation, therapy, Cardiology and Cardiovascular Medicine
Citation
Vafiadaki, E, Glijnis, P C, Doevendans, P A, Kranias, E G & Sanoudou, D 2023, 'Phospholamban R14del disease : The past, the present and the future', Frontiers in Cardiovascular Medicine, vol. 10, 1162205. https://doi.org/10.3389/fcvm.2023.1162205